Putnam Investments LLC Crinetics Pharmaceuticals, Inc. Transaction History

Putnam Investments LLC

  • $73 Billion
  • Q4 2023

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$15.49 - $19.05 $201 - $247
-13 Reduced 0.06%
23,338 $427,000
Q3 2022

Nov 14, 2022
SELL
$18.11 - $22.37 $7,660 - $9,462
-423 Reduced 1.78%
23,351 $458,000
Q2 2022

Aug 15, 2022
SELL
$16.49 - $27.64 $31,578 - $52,930
-1,915 Reduced 7.45%
23,774 $444,000
Q1 2022

May 16, 2022
SELL
$17.15 - $28.31 $32,945 - $54,383
-1,921 Reduced 6.96%
25,689 $564,000
Q4 2021

Feb 14, 2022
BUY
$19.35 - $28.41 $534,253 - $784,400
27,610 New
27,610 $785,000

Others Institutions Holding CRNX

# of Institutions
244
Shares Held
78.2M
Call Options Held
268K
Put Options Held
197K
View Full List

About Crinetics Pharmaceuticals, Inc.

CRNX Quotes by TradingView
  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.73B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Putnam Investments LLC Portfolio

Follow Putnam Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Putnam Investments LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email